Definitive Healthcare (NASDAQ:DH) Issues Q2 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its second quarter 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.090-0.090 for the period, compared to the consensus earnings per share estimate of 0.090. The company issued revenue guidance of $63.7 million-$63.7 million, compared to the consensus revenue estimate of $62.7 million. Definitive Healthcare also updated its FY 2024 guidance to 0.320-0.340 EPS.

Definitive Healthcare Price Performance

DH traded down $0.23 during trading on Tuesday, reaching $5.74. 3,696,056 shares of the company traded hands, compared to its average volume of 710,079. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.30 and a current ratio of 2.30. Definitive Healthcare has a 12-month low of $4.38 and a 12-month high of $11.97. The firm has a fifty day simple moving average of $5.55 and a 200 day simple moving average of $7.17. The company has a market cap of $676.92 million, a P/E ratio of -3.28, a PEG ratio of 4.36 and a beta of 1.30.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. The company had revenue of $63.48 million for the quarter, compared to analysts’ expectations of $64.00 million. On average, equities analysts forecast that Definitive Healthcare will post 0.1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DH shares. Stifel Nicolaus cut their target price on shares of Definitive Healthcare from $11.00 to $9.50 and set a buy rating for the company in a report on Wednesday, May 8th. Barclays cut their target price on shares of Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating for the company in a report on Thursday, May 9th. Canaccord Genuity Group cut their target price on shares of Definitive Healthcare from $10.00 to $8.00 and set a hold rating for the company in a report on Wednesday, May 8th. Deutsche Bank Aktiengesellschaft lowered their price target on Definitive Healthcare from $10.00 to $7.00 and set a hold rating for the company in a research report on Thursday, May 9th. Finally, William Blair restated an outperform rating on shares of Definitive Healthcare in a research report on Tuesday, May 14th. Eight analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Hold and a consensus target price of $9.56.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.